FLC
NAUT icon

Fifth Lane Capital’s Nautilus Biotechnolgy NAUT Stock Holding History

Fifth Lane Capital’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,200
Closed -$44K – 362
2022
Q1 		$44K Buy
+10,200
New +$41.9K 0.03% 178

Other funds holding NAUT

AEPBI
AH Equity Partners Bio II Menlo Park, California $144M AUM 54.61% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $329M AUM 64.12% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return
AI
ArchPoint Investors Coral Gables, Florida $473M AUM 49.24% 1-Year Est. Return

Fifth Lane Capital's NAUT Position: Q2 2022 in Review

Fifth Lane Capital sold out of Nautilus Biotechnolgy (NAUT) in Q2 2022, closing a stake of 10,200 shares — an estimated $44K sold.

Fifth Lane Capital first reported a position in NAUT in Q1 2022 and held it in 1 quarter. The position peaked at $44K in Q1 2022. 83 funds tracked by Wall St. Rank hold NAUT as of Q2 2022.

  • Fifth Lane Capital reported no remaining Nautilus Biotechnolgy position as of Q2 2022 after selling out during the quarter.
  • Fifth Lane Capital sold 10,200 Nautilus Biotechnolgy shares in Q2 2022, an estimated $44K.
  • Fifth Lane Capital first reported a position in Nautilus Biotechnolgy in Q1 2022 and held it in 1 quarter.
  • Fifth Lane Capital's Nautilus Biotechnolgy position peaked at $44K in Q1 2022.
  • 83 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2022.

Based on Fifth Lane Capital's 13F filing for Q2 2022, filed 15 Aug 2022.